Tolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis

Delcasso, B.; Goujon, Catherine; Hacard, F.; Delcroix, F.; Grande, Sophie; Berard, F.; Nicolas, Jean‐François; Nosbaum, Audrey

doi:10.1684/ejd.2018.3231

Cited by 7 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This good tolerance was recently confirmed in a daily practice cohort of 20 adults with AE. 4 We concluded from this study that MTX is very effective in AE, using a dosing regimen similar to or higher than in psoriasis (15-25 mg/weeks). In this respect, Czarnowicki et al 5 have recently reported that both skin-homing and systemic T-cell subsets show higher activation status in AE than in psoriasis.…”

mentioning

confidence: 64%

Methotrexate in atopic eczema. Comments to: Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

Goujon

Nicolas

Nosbaum

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 64%

Methotrexate in atopic eczema. Comments to: Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

Goujon

Nicolas

Nosbaum

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Thus, we considered the short‐term response rate to be 66% (29/44) for this study because itch is the hallmark symptom of AD. Second, for one study 36 we gave priority to the response rate that was assessed at the latest time for the computation of the e.s. of response rate.…”

Section: Results Of Sensitivity Analysismentioning

confidence: 99%

Methotrexate therapy for adult and paediatric moderate‐to‐severe atopic dermatitis: A PRISMA‐compliant meta‐analysis of data from daily practice

Wang,

Chen

2023

Aust J Dermatology

View full text Add to dashboard Cite

Of the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate‐to‐severe atopic dermatitis, 12 were non‐randomized controlled trial (non‐RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short‐term therapy were 77% [95% CI 55‐99] (four studies; adults) – comparable to 81% [54‐100] of RCTs (two studies; adults) (p = 0.63) – and 61% [43‐79] (two studies; children), and for medium/long‐term therapy were 88.9% [74.3‐100.0] (four studies; adults) and 77.7% [61.5–94.0] (three studies; children). Children had a markedly lower rate of treatment discontinuation due to side effects [2.0% (five studies; children) vs. 14.9% (six studies; adults)], but were more likely to experience gastrointestinal disorders {relative risk (RR) 2.0 [1.44‐2.71]}, fatigue (RR 2.3 [1.35‐3.72]), headache (RR 2.8 [1.23‐5.61]), and infections (RR 2.9 [2.18‐3.58]). Other adverse events (children vs. adults) included hepatic disorders (32/176 vs. 35/305) and blood and lymphatic system/bone marrow disorders (25/148 vs. 19/184). Four serious adverse events were reported (children). Evidence from daily practice was limited by bias in the selection of participants in the study.

show abstract

“…The group favoured methotrexate (15–25 mg/week) as both a first‐ (with or without bridging therapy) and second‐line therapy. They were also happy to consider combination with prednis(lo)one, ciclosporin, azathioprine and mycophenolate, but at a slightly reduced dose (10–15 mg/week). Methotrexate is generally well tolerated; this can be improved by subcutaneous administration …”

Section: Resultsmentioning

confidence: 99%

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Rademaker

Agnew

Andrews³

et al. 2019

Aust J Dermatology

View full text Add to dashboard Cite

With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real‐world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.

show abstract

Tolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis

Cited by 7 publications

References 4 publications

Methotrexate in atopic eczema. Comments to: Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

Methotrexate in atopic eczema. Comments to: Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

Methotrexate therapy for adult and paediatric moderate‐to‐severe atopic dermatitis: A PRISMA‐compliant meta‐analysis of data from daily practice

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Contact Info

Product

Resources

About